The role of epigenetics in arterial calcification

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Wu, Shan Shan ^a   Lin, Xiao ^b   Yuan, Ling Qing ^b   Liao, Er Yuan ^b  

^a People's Hospital of Pingxiang City   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; HISTONE;

ARTERY CALCIFICATION; CHROMATIN; CHROMATIN REMODELLING; DNA METHYLATION; DNA SEQUENCE; EPIGENETICS; GENE CONTROL; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HUMAN; NONHUMAN; REVIEW; ARTERY; BLOOD VESSEL CALCIFICATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY;

ARTERIES; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MICRORNAS; VASCULAR CALCIFICATION;

EID: 84937019529     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/320849     Document Type: Review

References (103)

1. W. G. Goodman, J. Goldin, B. D. Kuizon et al., "Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis,"The New England Journal of Medicine, vol. 342, no. 20, pp. 1478-1483, 2000.
2. F. Verbeke, W. van Biesen, E. Honkanen et al., "Prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the Calcification Outcome in Renal Disease (CORD) study," Clinical Journal of the American Society of Nephrology, vol. 6, no. 1, pp. 153-159, 2011.
3. A. N. Qasim, S. S. Martin, N. N. Mehta et al., "Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women," International Journal of Cardiology, vol. 150, no. 1, pp. 17-21, 2011.
4. I. E. Schauer, J. K. Snell-Bergeon, B. C. Bergman et al., "Insulin resistance, defective insulin-mediated fatty acid suppression, and coronary artery calcification in subjects with and without type 1 diabetes the CACTI study," Diabetes, vol. 60, no. 1, pp. 306-314, 2011.
5. R. Virmani, A. P. Burke, A. Farb, and F. D. Kolodgie, "Pathology of the vulnerable plaque," Journal of the American College of Cardiology, vol. 47, no. 8, pp. C13-C18, 2006.
6. Y. Vengrenyuk, L. Cardoso, and S. Weinbaum, "Micro-CT based analysis of a new paradigm for vulnerable plaque rupture: cellular microcalcifications in fibrous caps," Molecular and Cellular Biomechanics, vol. 5, no. 1, pp. 37-47, 2008.
7. T. Hoshino, L. A. Chow, J. J. Hsu et al., "Mechanical stress analysis of a rigid inclusion in distensible material: a model of atherosclerotic calcification and plaque vulnerability," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 297, no. 2, pp. H802-H810, 2009.
8. M. J. Duer, T. Friscić, D. Proudfoot et al., "Mineral surface in calcified plaque is like that of bone further evidence for regulated mineralization," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 11, pp. 2030-2034, 2008.
9. Y. Du, Y. Wang, L. Wang et al., "Cartilage oligomericmatrixprotein inhibits vascular smoothmuscle calcification by interacting with bone morphogenetic protein-2," Circulation Research, vol. 108, no. 8, pp. 917-928, 2011.
10. L.-Q. Yuan, J.-H. Zhu, H.-W. Wang et al., "RANKL is a downstreammediator for insulin-induced osteoblastic differentiation of vascular smooth muscle cells," PLoS ONE, vol. 6, no. 12, Article ID e29037, 2011.
11. Q.-H. Liang, Y. Jiang, X. Zhu et al., "Ghrelin attenuates the osteoblastic differentiation of vascular smooth muscle cells through the erk pathway," PLoS ONE, vol. 7, no. 4, Article ID e33126, 2012.
12. T. M. Doherty, L. A. Fitzpatrick, D. Inoue et al., "Molecular, endocrine, and genetic mechanisms of arterial calcification," Endocrine Reviews, vol. 25, no. 4, pp. 629-672, 2004.
13. F. Rutsch, Y. Nitschke, and R. Terkeltaub, "Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel," Circulation Research, vol. 109, no. 5, pp. 578-592, 2011.
14. R. Wallin, N. Wajih, G. Todd Greenwood, and D. C. Sane, "Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy," Medicinal Research Reviews, vol. 21, no. 4, pp. 274-301, 2001.
15. C. H. Waddington, "The epigenotype," International Journal of Epidemiology, vol. 41, no. 1, pp. 10-13, 2012.
16. A. D. Goldberg, C. D. Allis, and E. Bernstein, "Epigenetics: a landscape takes shape," Cell, vol. 128, no. 4, pp. 635-638, 2007.
17. M. Esteller, "Epigenetics in cancer,"The New England Journal of Medicine, vol. 358, pp. 1148-1159, 2008.
18. A. P. Feinberg, "Epigenetics at the epicenter of modern medicine," JAMA, vol. 299, no. 11, pp. 1345-1350, 2008.
19. M. Esteller, "Cancer epigenetics for the 21st century: what's next?" Genes and Cancer, vol. 2, no. 6, pp. 604-606, 2011.
20. M. Münzel, D. Globisch, and T. Carell, "5-hydroxymethylcytosine, the sixth base of the genome," Angewandte Chemie International Edition, vol. 50, no. 29, pp. 6460-6468, 2011.
21. A. Portela and M. Esteller, "Epigenetic modifications and human disease," Nature Biotechnology, vol. 28, no. 10, pp. 1057-1068, 2010.
22. L. M. Villeneuve and R. Natarajan, "The role of epigenetics in the pathology of diabetic complications," The American Journal of Physiology-Renal Physiology, vol. 299, no. 1, pp. F14-F25, 2010.
23. G. Weissen-Plenz, Y. Nitschke, and F. Rutsch, "Mechanisms of arterial calcification: spotlight on the inhibitors," Advances in Clinical Chemistry, vol. 46, pp. 263-293, 2008.
24. F. Rutsch and R. Terkeltaub, "Deficiencies of physiologic calcification inhibitors and low-grade inflammation in arterial calcification: lessons for cartilage calcification," Joint Bone Spine, vol. 72, no. 2, pp. 110-118, 2005.
25. A. Sweatt, D. C. Sane, S. M. Hutson, and R. Wallin, "Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats," Journal ofThrombosis and Haemostasis, vol. 1, no. 1, pp. 178-185, 2003.
26. M. Ketteler, P. Bongartz, R. Westenfeld et al., "Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study," The Lancet, vol. 361, no. 9360, pp. 827-833, 2003.
27. S. M. Moe and N. X. Chen, "Mechanisms of vascular calcification in chronic kidney disease," Journal of the American Society of Nephrology, vol. 19, no. 2, pp. 213-216, 2008.
28. T. Wada, M. D. McKee, S. Steitz, and C. M. Giachelli, "Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin," Circulation Research, vol. 84, no. 2, pp. 166-178, 1999.
29. P. A. Price, H. H. June, J. R. Buckley, and M. K. Williamson, "Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 10, pp. 1610-1616, 2001.
30. K. A. Hruska, S. Mathew, and G. Saab, "Bone morphogenetic proteins in vascular calcification," Circulation Research, vol. 97, no. 2, pp. 105-114, 2005.
31. P. Collin-Osdoby, "Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin," Circulation Research, vol. 95, no. 11, pp. 1046-1057, 2004.
32. G.-Y. Liu, Q.-H. Liang, R.-R. Cui et al., "Leptin promotes the osteoblastic differentiation of vascular smooth muscle cells from female mice by increasing RANKL expression," Endocrinology, vol. 155, no. 2, pp. 558-567, 2014.
33. L. L. Demer and Y. Tintut, "Vascular calcification: pathobiology of a multifaceted disease," Circulation, vol. 117, no. 22, pp. 2938-2948, 2008.
34. A. Tanimura, D. H. McGregor, and H. C. Anderson, "Matrix vesicles in atherosclerotic calcification," Proceedings of the Society for Experimental Biology and Medicine, vol. 172, no. 2, pp. 173-177, 1983.
35. D. Proudfoot, J. N. Skepper, L. Hegyi, M. R. Bennett, C. M. Shanahan, and P. L. Weissberg, "Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies," Circulation Research, vol. 87, no. 11, pp. 1055-1062, 2000.
36. P.-F. Shan, Y. Lu, R.-R. Cui, Y. Jiang, L.-Q. Yuan, and E.-Y. Liao, "Apelin attenuates the osteoblastic differentiation of vascular smoothmuscle cells," PLoS ONE, vol. 6, no. 3, Article IDe17938, 2011.
37. X.-B. Liao, X.-M. Zhou, J.-M. Li et al., "Taurine inhibits osteoblastic differentiation of vascular smooth muscle cells via the ERK pathway," Amino Acids, vol. 34, no. 4, pp. 525-530, 2008.
38. M. Schoppet, R. C. Shroff, L. C. Hofbauer, and C. M. Shanahan, "Exploring the biology of vascular calcification in chronic kidney disease: what's circulating?" Kidney International, vol. 73, no. 4, pp. 384-390, 2008.
39. L. L. Demer, Y. Tintut, and F. Parhami, "Novel mechanisms in accelerated vascular calcification in renal disease patients," Current Opinion in Nephrology and Hypertension, vol. 11, no. 4, pp. 437-443, 2002.
40. H. Yang, G. Curinga, and C. M. Giachelli, "Elevated extracellular calcium levels induce smoothmuscle cell matrix mineralization in vitro," Kidney International, vol. 66, no. 6, pp. 2293-2299, 2004.
41. S. Jono, M. D. McKee, C. E. Murry et al., "Phosphate regulation of vascular smooth muscle cell calcification," Circulation Research, vol. 87, no. 7, pp. e10-e17, 2000.
42. M. Abedin, Y. Tintut, and L. L. Demer, "Vascular calcification: Mechanisms and clinical ramifications," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 7, pp. 1161-1170, 2004.
43. J. D. Miller, Y. Chu, R. M. Brooks, W. E. Richenbacher, R. Peña-Silva, and D. D. Heistad, "Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans," Journal of the American College of Cardiology, vol. 52, no. 10, pp. 843-850, 2008.
44. C. Y. Y. Yip, J.-H. Chen, R. Zhao, and C. A. Simmons, "Calcification by valve interstitial cells is regulated by the stiffness of the extracellular matrix," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 6, pp. 936-942, 2009.
45. X. Li, H.-Y. Yang, and C. M. Giachelli, "Role of the sodiumdependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification," Circulation Research, vol. 98, no. 7, pp. 905-912, 2006.
46. K. Amann, "Media calcification and intima calcification are distinct entities in chronic kidney disease," Clinical Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1599-1605, 2008.
47. J. L. Hunt, R. Fairman, M. E. Mitchell et al., "Bone formation in carotid plaques: a clinicopathological study," Stroke, vol. 33, no. 5, pp. 1214-1219, 2002.
48. A. P. Burke, A. Taylor, A. Farb, G. T. Malcom, and R. Virmani, "Coronary calcification: insights from sudden coronary death victims," Zeitschrift fur Kardiologie, vol. 89, supplement, no. 2, pp. S49-S53, 2000.
49. A. Farzaneh-Far, D. Proudfoot, C. Shanahan, and P. L. Weissberg, "Vascular and valvar calcification: recent advances," Heart, vol. 85, no. 1, pp. 13-17, 2001.
50. M. E. Edmonds, N. Morrison, J. W. Laws, and P. J. Watkins, "Medial arterial calcification and diabetic neuropathy," British Medical Journal, vol. 284, no. 6320, pp. 928-930, 1982.
51. J. G. Mönckeberg, " Uber die reine Mediaverkalkung der Extremitätenarterien und ihr Verhalten zur Arteriosklerose," Virchows Archiv für pathologische Anatomie und Physiologie und für klinische Medizin, vol. 171, no. 1, pp. 141-167, 1903.
52. M.-C. Wang, W.-C. Tsai, J.-Y. Chen, and J.-J. Huang, "Stepwise increase in arterial stiffness corresponding with the stages of chronic kidney disease," The American Journal of Kidney Diseases, vol. 45, no. 3, pp. 494-501, 2005.
53. T. C. Lin, Y. Tintut, A. Lyman, W. MacK, L. L. Demer, and T. K. Hsiai, "Mechanical response of a calcified plaquemodel to fluid shear force," Annals of Biomedical Engineering, vol. 34, no. 10, pp. 1535-1541, 2006.
54. L. van Speybroeck, "From epigenesis to epigenetics: the case of C. H. Waddington," Annals of the New York Academy of Sciences, vol. 981, pp. 61-81, 2002.
55. T. Kouzarides, "Chromatin modifications and their function," Cell, vol. 128, no. 4, pp. 693-705, 2007.
56. R. Holliday and J. E. Pugh, "DNA modification mechanisms and gene activity during development. Developmental clocks may depend on the enzymic modification of specific bases in repeated DNA sequences," Science, vol. 187, no. 4173, pp. 226-232, 1975.
57. S. Saxonov, P. Berg, and D. L. Brutlag, "A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters," Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1412-1417, 2006.
58. R. A. Irizarry, C. Ladd-Acosta, B. Wen et al., "The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specificCpGisland shores,"NatureGenetics, vol. 41, no. 2, pp. 178-186, 2009.
59. Z.-X. Chen, J. R. Mann, C.-L. Hsieh, A. D. Riggs, and F. Chédin, "Physical and functional interactions between the humanDNMT3L protein andmembers of the de novomethyltransferase family," Journal of Cellular Biochemistry, vol. 95, no. 5, pp. 902-917, 2005.
60. C. Holz-Schietinger and N. O. Reich, "Theinherent processivity of the human de Novo methyltransferase 3A (DNMT3A) is enhanced by DNMT3L," The Journal of Biological Chemistry, vol. 285, no. 38, pp. 29091-29100, 2010.
61. M. G. Goll, F. Kirpekar, K. A. Maggert et al., "Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2," Science, vol. 311, no. 5759, pp. 395-398, 2006.
62. S. Kangaspeska, B. Stride, R. Métivier et al., "Transient cyclical methylation of promoter DNA," Nature, vol. 452, no. 7183, pp. 112-115, 2008.
63. R. Métivier, R. Gallais, C. Tiffoche et al., "Cyclical DNA methylation of a transcriptionally active promoter," Nature, vol. 452, pp. 45-50, 2008.
64. L. D. Moore, T. Le, and G. Fan, "DNA methylation and its basic function," Neuropsychopharmacology, vol. 38, no. 1, pp. 23-38, 2013.
65. L. Lopez-Serra and M. Esteller, "Proteins that bind methylated DNA and human cancer: reading the wrong words," British Journal of Cancer, vol. 98, no. 12, pp. 1881-1885, 2008.
66. M. Esteller, "Epigenetic gene silencing in cancer: the DNA hypermethylome," Human Molecular Genetics, vol. 16, no. 1, pp. R50-R59, 2007.
67. A. Kuroda, T. A. Rauch, I. Todorov et al., "Insulin gene expression is regulated by DNA methylation," PLoS ONE, vol. 4, no. 9, Article ID e6953, 2009.
68. A. M. de Oca, J. A. Madueño, J. M. Martinez-Moreno et al., "High-phosphate-induced calcification is related to SM22α promotermethylation in vascular smoothmuscle cells," Journal of Bone andMineral Research, vol. 25, no. 9, pp. 1996-2005, 2010.
69. B. M. Turner, "Histone acetylation as an epigenetic determinant of long-termtranscriptional competence," Cellular andMolecular Life Sciences, vol. 54, no. 1, pp. 21-31, 1998.
70. R. F. Luco, Q. Pan, K. Tominaga, B. J. Blencowe, O. M. Pereira-Smith, and T. Misteli, "Regulation of alternative splicing by histonemodifications," Science, vol. 327, no. 5968, pp. 996-1000, 2010.
71. D. Huertas, R. Sendra, and P. Muñoz, "Chromatin dynamics coupled toDNArepair," Epigenetics, vol. 4, no. 1, pp. 31-42, 2009.
72. M. S. Cosgrove and C. Wolberger, "How does the histone code work?" Biochemistry and Cell Biology, vol. 83, no. 4, pp. 468-476, 2005.
73. T. Jenuwein and C. D. Allis, "Translating the histone code," Science, vol. 293, no. 5532, pp. 1074-1080, 2001.
74. G. G. Wang, C. D. Allis, and P. Chi, "Chromatin remodeling and cancer, part I: covalent histone modifications," Trends in Molecular Medicine, vol. 13, no. 9, pp. 363-372, 2007.
75. A. Kimura, K. Matsubara, and M. Horikoshi, "A decade of histone acetylation: marking eukaryotic chromosomes with specific codes," Journal of Biochemistry, vol. 138, no. 6, pp. 647-662, 2005.
76. S. Thiagalingam, K.-H. Cheng, H. J. Lee, N. Mineva, A. Thiagalingam, and J. F. Ponte, "Histone deacetylases: unique players in shaping the epigenetic histone code," Annals of the New York Academy of Sciences, vol. 983, pp. 84-100, 2003.
77. A. Lusser and J. T. Kadonaga, "Chromatin remodeling by ATPdependent molecular machines," BioEssays, vol. 25, no. 12, pp. 1192-1200, 2003.
78. P. B. Becker and W. Hörz, "ATP-dependent nucleosome remodeling," Annual Reviewof Biochemistry, vol. 71, pp. 247-273, 2002.
79. J. M. Miano, X. Long, and K. Fujiwara, "Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus," The American Journal of Physiology-Cell Physiology, vol. 292, no. 1, pp. C70-C81, 2007.
80. J. M. Miano, "Serum response factor: toggling between disparate programs of gene expression," Journal of Molecular and Cellular Cardiology, vol. 35, no. 6, pp. 577-593, 2003.
81. P. Qiu and L. Li, "Histone acetylation and recruitment of serum responsive factor and CREB-binding protein onto SM22 promoter during SM22 gene expression," Circulation Research, vol. 90, no. 8, pp. 858-865, 2002.
82. O. G. McDonald, B. R. Wamhoff, M. H. Hoofnagle, and G. K. Owens, "Control of SRF binding to CArG box chromatin regulates smooth muscle gene expression in vivo," The Journal of Clinical Investigation, vol. 116, no. 1, pp. 36-48, 2006.
83. D. Cao, Z. Wang, C.-L. Zhang et al., "Modulation of smooth muscle gene expression by association of histone acetyltransferases and deacetylases with myocardin," Molecular and Cellular Biology, vol. 25, no. 1, pp. 364-376, 2005.
84. V. Ambros, "The functions of animal microRNAs," Nature, vol. 431, no. 7006, pp. 350-355, 2004.
85. M. Faller and F. Guo, "MicroRNA biogenesis: there's more than one way to skin a cat," Biochimica et Biophysica Acta: Gene Regulatory Mechanisms, vol. 1779, no. 11, pp. 663-667, 2008.
86. I. Bentwich, A. Avniel, Y. Karov et al., "Identification of hundreds of conserved and nonconserved human microRNAs," Nature Genetics, vol. 37, no. 7, pp. 766-770, 2005.
87. M. S. Jamaluddin, S. M. Weakley, L. Zhang et al., "MiRNAs: roles and clinical applications in vascular disease," Expert Review of Molecular Diagnostics, vol. 11, no. 1, pp. 79-89, 2011.
88. C. Goettsch, M. Rauner, N. Pacyna, U. Hempel, S. R. Bornstein, and L. C. Hofbauer, "MiR-125b regulates calcification of vascular smoothmuscle cells,"TheAmerican Journal of Pathology, vol. 179, no. 4, pp. 1594-1600, 2011.
89. P. Wen, H. Cao, L. Fang et al., "miR-125b/Ets1 axis regulates transdifferentiation and calcification of vascular smoothmuscle cells in a high-phosphate environment," Experimental Cell Research, vol. 322, no. 2, pp. 302-312, 2014.
90. Y. Du, C. Gao, Z. Liu et al., "Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by miR-29 repression mediates vascular smooth muscle calcification," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 11, pp. 2580-2588, 2012.
91. J. A. F. Balderman, H.-Y. Lee, C. E. Mahoney et al., "Bone morphogenetic protein-2 decreases microRNA-30b and microRNA-30c to promote vascular smooth muscle cell calcification," Journal of the American Heart Association, vol. 1, no. 6, Article ID e003905, 2012.
92. X.-B. Liao, Z.-Y. Zhang, K. Yuan et al., "MiR-133a modulates osteogenic differentiation of vascular smooth muscle cells," Endocrinology, vol. 154, no. 9, pp. 3344-3352, 2013.
93. R.-R. Cui, S.-J. Li, L.-J. Liu et al., "MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo," Cardiovascular Research, vol. 96, no. 2, pp. 320-329, 2012.
94. T. Gui, G. Zhou, Y. Sun et al., "MicroRNAs that target Ca2+ transporters are involved in vascular smooth muscle cell calcification," Laboratory Investigation, vol. 92, no. 9, pp. 1250-1259, 2012.
95. N. C. W. Mackenzie, K. A. Staines, D. Zhu, P. Genever, and V. E. MacRae, "miRNA-221 and miRNA-222 synergistically function to promote vascular calcification," Cell Biochemistry and Function, vol. 32, no. 2, pp. 209-216, 2014.
96. A. Y. Rangrez, E. M'Baya-Moutoula, V. Metzinger-Le Meuth et al., "Inorganic phosphate accelerates the migration of vascular smoothmuscle cells: evidence for the involvement of miR-223," PLoS ONE, vol. 7, no. 10, Article IDe47807, 2012.
97. M. F. Fraga and M. Esteller, "Epigenetics and aging: the targets and the marks," Trends in Genetics, vol. 23, no. 8, pp. 413-418, 2007.
98. A. J. Patterson, M. Chen, Q. Xue, D. Xiao, and L. Zhang, "Chronic prenatal hypoxia induces epigenetic programming of PKCε gene repression in rat hearts," Circulation Research, vol. 107, no. 3, pp. 365-373, 2010.
99. Y. Saito, G. Liang, G. Egger et al., "Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells," Cancer Cell, vol. 9, no. 6, pp. 435-443, 2006.
100. V. Santini, A. Gozzini, and G. Ferrari, "Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application," Current DrugMetabolism, vol. 8, no. 4, pp. 383-394, 2007.
101. A. Granger, I. Abdullah, F. Huebner et al., "Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice," FASEB Journal, vol. 22, no. 10, pp. 3549-3560, 2008.
102. E. Fabbri, E. Brognara, M. Borgatti et al., "miRNAtherapeutics: delivery and biological activity of peptide nucleic acids targeting miRNAs," Epigenomics, vol. 3, no. 6, pp. 733-745, 2011.
103. J. Krützfeldt, N. Rajewsky, R. Braich et al., "Silencing of microRNAs in vivo with "antagomirs"," Nature, vol. 438, no. 7068, pp. 685-689, 2005.